103 related articles for article (PubMed ID: 32381460)
1. CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
Marciscano AE; Barbieri CE
Eur Urol; 2020 Nov; 78(5):680-681. PubMed ID: 32381460
[No Abstract] [Full Text] [Related]
2. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
3. Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
Iwasawa T; Kosaka T; Yasumizu Y; Hongo H; Yanai Y; Baba Y; Matsumoto K; Nakamura K; Nishihara H; Oya M
Int J Clin Oncol; 2022 Dec; 27(12):1867-1873. PubMed ID: 36271301
[TBL] [Abstract][Full Text] [Related]
4. CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Yanai Y; Kosaka T; Nakamura K; Aimono E; Matsumoto K; Morita S; Mikami S; Nishihara H; Oya M
Cancer Sci; 2020 Dec; 111(12):4652-4655. PubMed ID: 33038052
[TBL] [Abstract][Full Text] [Related]
5. In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer".
Valle LF; Nickols NG; Yamoah K; Garraway IP; Maxwell KN; Lynch JA
Oncologist; 2023 Nov; 28(11):e1129-e1130. PubMed ID: 37706534
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer.
Sartor O; Jang A; Ledet E
Oncologist; 2023 Nov; 28(11):e1127-e1128. PubMed ID: 37589230
[TBL] [Abstract][Full Text] [Related]
7.
Lotan TL; Antonarakis ES
Clin Cancer Res; 2021 Jan; 27(2):380-382. PubMed ID: 33199495
[TBL] [Abstract][Full Text] [Related]
8. Analysis of CDK12 alterations in a pan-cancer database.
Pan E; Cabal A; Javier-DesLoges J; Patel D; Panian J; Lee S; Shaya J; Nonato T; Xu X; Stewart T; Rose B; Shabaik A; Cohen E; Kurzrock R; Tamayo P; McKay RR
Cancer Med; 2022 Feb; 11(3):753-763. PubMed ID: 34898046
[TBL] [Abstract][Full Text] [Related]
9. CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
Wang X; Chen H; Luo J; Xie L
Eur Urol; 2020 Mar; 77(3):342-343. PubMed ID: 31694772
[No Abstract] [Full Text] [Related]
10. Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer.
Maddison LA; Huss WJ; Barrios RM; Greenberg NM
Prostate; 2004 Mar; 58(4):335-44. PubMed ID: 14968434
[TBL] [Abstract][Full Text] [Related]
11. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
12. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Popova T; Manié E; Boeva V; Battistella A; Goundiam O; Smith NK; Mueller CR; Raynal V; Mariani O; Sastre-Garau X; Stern MH
Cancer Res; 2016 Apr; 76(7):1882-91. PubMed ID: 26787835
[TBL] [Abstract][Full Text] [Related]
13. Role and therapeutic potential of CDK12 in human cancers.
Chilà R; Guffanti F; Damia G
Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells.
Lim JT; Mansukhani M; Weinstein IB
Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5156-61. PubMed ID: 15790678
[TBL] [Abstract][Full Text] [Related]
15. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
[TBL] [Abstract][Full Text] [Related]
16. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Ekumi KM; Paculova H; Lenasi T; Pospichalova V; Bösken CA; Rybarikova J; Bryja V; Geyer M; Blazek D; Barboric M
Nucleic Acids Res; 2015 Mar; 43(5):2575-89. PubMed ID: 25712099
[TBL] [Abstract][Full Text] [Related]
17. Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas.
Bartkowiak B; Yan C; Greenleaf AL
Biochim Biophys Acta; 2015 Sep; 1849(9):1179-87. PubMed ID: 26189575
[TBL] [Abstract][Full Text] [Related]
18. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
[TBL] [Abstract][Full Text] [Related]
20. Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells.
Cipriano SC; Chen YQ
Oncogene; 1998 Sep; 17(12):1549-56. PubMed ID: 9794232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]